Dimerix Ltd (SBMJF PINK) stock market data APIs
$0.3521
0(0%)
as of March 12, 2026
Try our APIs with
free plan!
Dimerix Ltd Financial Data Overview
Price chart is built with
Anychart
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease, diabetic kidney disease, and ARDS associated with COVID-19; and DMX-700 for orphan respiratory/renal disease, as well as proprietary Receptor-HIT assay technology. The company is headquartered in Fitzroy, Australia.
Prev. Close
0.3521
Open
0.3521
High
0.3521
Low
0.3521
52 wk Range
0.25-0.35
Market Cap
210 M
Shares Outstanding
600 M
Revenue
7 416 K
Beta
0.181
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Dimerix Ltd data using free add-ons & libraries
Get Dimerix Ltd Fundamental Data
Dimerix Ltd Fundamental data includes:
- Net Revenue: 7 416 K
- EBITDA: -40 293 896
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-02-23
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Dimerix Ltd News
New
Just The Facts: Archtis, Critical Resources, Telix Pharmaceuticals, Dimerix
In today's Just The Facts.. archTIS has deployed its NC Protect software into the U.S. Department of Defense’s Microsoft DoD365 production environment. The company has also renewed 1,000 licences an...
DMX-200 ACTION3 PHASE 3 TRIAL COMPLETES RECRUITMENT
Recruitment successfully completed in Dimerix' ACTION3 Phase 3 clinical trial[1], which has recruited and dosed its target 286th adult patient The ACTION3 Phase 3 trial explores the efficacy and safet...
ASX Penny Stocks To Consider In December 2025
As the Australian market shows signs of a potential rally to close out the year, investors are eyeing opportunities that extend beyond the major indices. Penny stocks, often associated with smaller or...
ASX Penny Stocks Spotlight Dimerix And Two More Hidden Gems
Australian shares are showing signs of consolidation after a recent bullish surge, with the ASX 200 futures indicating a slight decline. Amid such market dynamics, investors often seek opportunities i...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
